Tesaro gets its PD-1 reg­is­tra­tion study start­ed, hunt­ing ac­cel­er­at­ed OK; Ul­tragenyx hus­tles in­to PhI­II

→ Tesaro $TSRO has launched a reg­is­tra­tion study for its PD-1 drug TSR-042, which was de­vel­oped in a col­lab­o­ra­tion with Anap­tys­Bio. The biotech — which is gun­ning for an ac­cel­er­at­ed ap­proval — is plan­ning to start a se­ries of com­bo ef­forts that match the check­point with the new­ly ap­proved Ze­ju­la, TSR-022, an an­ti-TIM-3 an­ti­body, and TSR-033, and an­ti-LAG-3 an­ti­body.

→ No­va­to, CA-based Ul­tragenyx $RARE launched a Phase III study of UX007 for the treat­ment of Glu­cose Trans­porter Type 1 De­fi­cien­cy Syn­drome (Glut1 DS) pa­tients ex­pe­ri­enc­ing dis­abling parox­ys­mal move­ment dis­or­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER